[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"peritoneal-carcinoma\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:peritoneal-carcinoma":29},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,6,0,[8,62,86,126,149,177],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":36,"overallStatus":50,"whyStopped":4,"lastUpdateSubmitDate":51,"lastUpdatePostDateStruct":52,"startDateStruct":55,"completionDateStruct":57,"leadSponsor":59,"locationsCount":61},"100538389","phase-2-study-of-acute-normovolemic-hemodilution-anh-in-people-with-ovarian-cancer-who-are-having-cytoreductive-surgery-100538389",false,"NCT06290193","Study of Acute Normovolemic Hemodilution (ANH) in People With Ovarian Cancer Who Are Having Cytoreductive Surgery","A Prospective Randomized Trial of Acute Normovolemic Hemodilution (ANH) in Patients Undergoing Cytoreductive Surgery for Ovarian Cancer","Inclusion Criteria:\n\n* Adults (≥18 years)\n* BLOODS score ≥2 as calculated by surgeon\n* High preoperative suspicion (or diagnosis) of advanced primary epithelial ovarian, fallopian tube, or primary peritoneal carcinoma (stage IIIC or IV), as determined by CT or MRI of the abdomen\u002Fpelvis\n* Planned for exploratory laparotomy and primary or interval cytoreductive surgery\n* Preoperative hemoglobin concentration ≥10 mg\u002Fdl within 45 days of surgery\n* Patients scheduled for cytoreductive surgery, with or without other planned procedures o Note: Patients scheduled for only diagnostic laparoscopy should not be included\n\nExclusion Criteria:\n\n* A history of active coronary artery disease\n\n  o Patients with a history of coronary artery disease will be eligible if they have had a cardiac stress study showing no reversible ischemia and normal LV function within 45 days of surgery.\n* A history of cerebrovascular disease\n* A history of congestive heart failure\n* A history of uncontrolled hypertension\n* A history of restrictive or obstructive pulmonary disease\n* A history of renal dysfunction (Cr \\>1.6 mg\u002Fdl)\n* Abnormal coagulation parameters (INR \\>1.5 not on coumadin, or platelet count \\\u003C100,000 mcL)\n* Presence of active infection\n* Evidence of hepatic metabolic disorder (bilirubin \\>2 mg\u002Fdl, ALT \\>75 U\u002FL in the absence of biliary tract obstruction)\n* Preoperative autologous blood donation within last 30 days or plan to donate autologous blood prior to surgery\n* Refusal to accept allogenic or autologous blood transfusion\n* Patients scheduled for cytoreductive surgery with planned Hyperthermic Intraperitoneal Chemotherapy (HIPEC)","ALL","18 Years",{"count":19,"type":20},86,"ESTIMATED","INTERVENTIONAL",[23],"PHASE2","Participants will be scheduled for primary cytoreductive surgery as part of their standard care. Before surgery, participants will be assigned by chance to a study group. Depending on which group they are in, they will receive either acute normovolemic hemodilution\u002FANH during surgery or standard surgical management during surgery. The researchers think acute normovolemic hemodilution\u002FANH may decrease the need for allogenic blood transfusion\u002FABT in people having primary cytoreductive surgery.",[26,27,28,29,30,31,32,33,34,35],"Ovarian Cancer","Fallopian Tube Carcinoma","Ovarian Carcinoma","Peritoneal Carcinoma","Ovarian Cancer Stage IIIC","Fallopian Tube Cancer Stage IIIC","Ovarian Cancer Stage IV","Fallopian Tube Cancer Stage IV","Fallopian Tube Cancer","Peritoneal Cancer",[37,38,39,40,41,42,43,44,45,46,47,48,49],"ovarian cancer","ovarian carcinoma","ovarian cancer stage IIIC","ovarian cancer stage IV","fallopian tube cancer","fallopian tube carcinoma","fallopian tube cancer stage IIIC","fallopian tube cancer stage IV","peritoneal cancer","peritoneal carcinoma","Acute Normovolemic Hemodilution","Memorial Sloan Kettering Cancer Center","23-392","RECRUITING","2026-03-31",{"date":53,"type":54},"2026-04-01","ACTUAL",{"date":56,"type":54},"2024-02-23",{"date":58,"type":20},"2029-02-23",{"name":48,"class":60},"OTHER",7,{"id":63,"slug":64,"hasResults":11,"nctId":65,"briefTitle":66,"officialTitle":66,"acronym":4,"eligibilityCriteria":67,"healthyVolunteers":11,"sex":68,"minAge":69,"maxAge":4,"enrollmentInfo":70,"targetDuration":4,"studyType":72,"phases":4,"briefSummary":73,"conditions":74,"keywords":4,"overallStatus":50,"whyStopped":4,"lastUpdateSubmitDate":76,"lastUpdatePostDateStruct":77,"startDateStruct":79,"completionDateStruct":81,"leadSponsor":83,"locationsCount":85},"100308555","prospective-cohort-study-of-germline-variant-carriers-with-brca1-or-brca2-100308555","NCT03296826","Prospective Cohort Study of Germline Variant Carriers With BRCA1 or BRCA2","Inclusion Criteria:\n\n1. Women carrying BRCA1\u002F2 variants (those with either BRCA1 or BRCA2 variants, or those carrying both variants) and women carrying a variant of uncertain significance (VUS).\n2. Women who have received sufficient genetic counseling at any medical institution, prior to enrollment to the study.\n3. Women who provide consent should be 20 years of age or older.\n4. Women who provide written consent.\n\nExclusion Criteria:\n\n1. Women without ovarian or fallopian tube cancer at the time of informed consent.\n2. Women previously diagnosed with ovarian, fallopian tube, or peritoneal cancer, and not excluding those with a personal history of breast cancer development.\n3. Other individuals considered inappropriate for involvement in this study by the investigator.","FEMALE","20 Years",{"count":71,"type":20},600,"OBSERVATIONAL","To determine the incidence and risk factors in the development of ovarian, fallopian tube, and peritoneal cancers in Japanese women carrying Breast Cancer Susceptibility Gene (BRCA)1\u002F2 variants.",[75,28,27,29],"BRCA1 and\u002For BRCA2 Variant Carriers","2026-01-30",{"date":78,"type":54},"2026-02-03",{"date":80,"type":54},"2017-11-08",{"date":82,"type":20},"2032-03-31",{"name":84,"class":60},"Translational Research Center for Medical Innovation, Kobe, Hyogo, Japan",1,{"id":87,"slug":88,"hasResults":11,"nctId":89,"briefTitle":90,"officialTitle":91,"acronym":92,"eligibilityCriteria":93,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":94,"enrollmentInfo":95,"targetDuration":4,"studyType":21,"phases":97,"briefSummary":99,"conditions":100,"keywords":111,"overallStatus":50,"whyStopped":4,"lastUpdateSubmitDate":117,"lastUpdatePostDateStruct":118,"startDateStruct":120,"completionDateStruct":122,"leadSponsor":124,"locationsCount":85},"100593065","phase-1-intra-tumoral-it-injection-of-vvdd-hil2-2-rg-1-for-metastatic-gastrointestinal-and-peritoneal-tumors-100593065","NCT07001592","Intra-tumoral (IT) Injection of vvDD-hIL2-2-RG-1 for Metastatic Gastrointestinal and Peritoneal Tumors","A Phase I Dose-Escalation Trial of vvDD-hIL2-2-RG-1 (Vaccina Virus Double Deleted) Administered by Intra-tumoral (IT) Injection for Metastatic Gastrointestinal and Peritoneal Tumors","RIOT3","Inclusion Criteria:\n\n1. Males or females age, 18 to \\\u003C 70 years at the time of consent\n2. Histologically confirmed metastases from gastrointestinal tumors with molecular determinants for MSI and KRAS.\n3. For microsatellite stable (MSS) tumors, subjects must have failed (or be ineligible for) standard 1st and 2nd line chemotherapy. For microsatellite instability-high (MSI-H) tumors, subjects must also have failed (or be ineligible for) systemic immunotherapy.\n4. Karnofsky Performance Status (KPS) of \\> 70\n5. Anticipated survival of at least 12 weeks.\n6. Written informed consent in accordance with national, local, and institutional guidelines obtained prior to any study procedures (subject or subject's legally authorized representative (LAR) must have the ability to understand and willingness to sign a written informed consent).\n7. Adequate bone marrow function: WBC \\> 2,000 and \\\u003C50,000 cells\u002Fmm3, ANC \\> 1,000 cells\u002Fmm3, hemoglobin \\>8 g\u002FdL, and platelet count \\>100,000 cells\u002Fmm3.\n8. Adequate renal function: serum creatinine level ≤ 2xULN\n9. Adequate liver function: Serum bilirubin \\\u003C 1.5 x ULN\n10. Acceptable coagulation status: INR \\\u003C ULN +15%. All patients must be able to suspend anticoagulant therapy for study specific biopsies and intra-tumoral injection.\n11. Women of childbearing potential (defined as all women physiologically capable of becoming pregnant) must have negative serum or urine pregnancy test.\n12. If sexually active, to prevent pregnancy and to prevent the spread of virus, subject must use an acceptable method of contraception as well as barrier contraception from screening through 6 weeks following study treatment with vvDD-hIL-2-RG-1.\n13. Subjects must be willing to comply with all study procedures, requirements, adhere to post-treatment care instructions and follow-up examinations.\n14. Have measurable disease based on RECIST 1.1 criteria.\n15. Have at least one tumor at least 1 cm in diameter amenable to safe intra-tumoral injection.\n\nExclusion Criteria:\n\n1. Pregnant or nursing an infant.\n2. Systemic corticosteroid or other immunosuppressive medication use within 2 weeks of the study treatment.\n3. Significant immunodeficiency (e.g. due to underlying illness and\u002For medication) in subject or household contacts (must be able to avoid household contact with immunodeficient person for 3 weeks).\n4. Clinically significant active infection or uncontrolled medical condition (e.g., pulmonary, neurological, cardiovascular, gastrointestinal, genitourinary) considered high risk for investigational new drug treatment, per investigator discretion.\n5. Active eczema or psoriasis or other inflammatory skin conditions\n6. Unstable cardiac disease which includes but is not limited to any of the following within 6 months prior to study entry: myocardial infarction (MI), unstable angina, congestive heart failure, myocarditis, ventricular arrhythmias diagnosed and requiring medication.\n\n   * New York Heart Association functional class III-IV heart failure on active treatment\n   * Pulse oximetry of \\\u003C 90% in room air at rest\n7. Subjects who have received radiation, chemotherapy or other potentially immunosuppressive therapy within 2 weeks prior to study screening and within 4 weeks prior to anticipated vvDD-hIL-2-RG-1 treatment.\n8. Experienced a severe systemic reaction or side-effect as a result of a previous smallpox vaccination.\n9. Subjects who, in the opinion of the Investigator, have a medical condition that would subject the subject to prohibitive risk by participation in this study, or who may be unable to safely complete the required tumor biopsies.\n10. Subjects with household contacts who are children \\\u003C 5 years old, have active eczema, psoriasis or other inflammatory skin conditions or have a significant immunodeficiency due to underlying illness (e.g. human immunodeficiency virus) and\u002For medication (e.g. systemic corticosteroids) will be excluded unless alternate living arrangements can be made during the subject's active dosing period and for three weeks following the study medication.\n11. Vaccination with a live virus in the previous 60 days prior to Day 0.\n12. Inability or unwillingness to give informed consent.\n13. Is unable or unwilling to comply with protocol follow-up requirements. -","69 Years",{"count":96,"type":20},18,[98],"PHASE1","This research study aims to evaluate the safety and determine the optimal dose of a new experimental drug, vvDD-hIL2 (vaccinia virus double-deleted human interleukin 2), in patients with advanced abdominal cancer. The study will involve three dose levels, with three to six patients enrolled at each level.\n\nvvDD-hIL2 is a genetically modified vaccinia virus, derived from the virus previously used for smallpox vaccination. The modification is intended to target and destroy tumors while minimizing harm to healthy tissues by stimulating the body's immune response.\n\nParticipants will receive an injection of vvDD-hIL2 directly into their abdominal tumors at AHN West Penn. The study team will monitor for side effects and assess tumor response to the treatment.\n\nActive participation will last up to two months, involving seven clinic visits and approximately four lab visits at AHN West Penn Hospital. Visits will include standard of care procedures as well as study-specific tests and exams. Most visits will last one to two hours, with some extending to two to three hours. The drug administration day will require a twelve-hour visit.\n\nEffectiveness and side effects will be evaluated through blood draws, oral swabs, urinalysis and tissue biopsies. Tissue samples will be used for genomic analysis and stored for potential future research. Data collected may also be used for future research purposes.\n\nPrevious human trials of vvDD-hIL2 have reported side effects such as pain, rash or inflammation at the injection site, low-grade fevers, flu-like symptoms, and fatigue. There is a rare risk of rash transmission to close contacts with skin openings, and information on limiting contact and managing rash development will be provided.",[101,102,103,104,105,106,107,35,29,108,109,110],"Gastric Neoplasms","Esophageal Cancer","Liver Cancer","Liver Metastasis","MSS-CRC","MSS","Gastric Adenocarcinoma","Peritoneal Metastases","MSI-H","Gastric Cancer",[112,113,114,115,116],"Oncolytic virus","vaccinia","immunotherapy","intra-tumoral","intra-peritoneal","2025-06-02",{"date":119,"type":54},"2025-06-03",{"date":121,"type":54},"2025-05-06",{"date":123,"type":20},"2028-05",{"name":125,"class":60},"Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute)",{"id":127,"slug":128,"hasResults":11,"nctId":129,"briefTitle":130,"officialTitle":131,"acronym":4,"eligibilityCriteria":132,"healthyVolunteers":11,"sex":68,"minAge":17,"maxAge":4,"enrollmentInfo":133,"targetDuration":4,"studyType":21,"phases":135,"briefSummary":136,"conditions":137,"keywords":4,"overallStatus":138,"whyStopped":4,"lastUpdateSubmitDate":139,"lastUpdatePostDateStruct":140,"startDateStruct":142,"completionDateStruct":144,"leadSponsor":146,"locationsCount":85},"100581139","phase-1-sct-001-car-t-cells-therapy-for-relapsed-and-refractory-ovarian-cancer-100581139","NCT06846424","SCT-001 CAR T Cells Therapy for Relapsed and Refractory Ovarian Cancer","A Clinical Study to Evaluate the Safety and Tolerability of SCT-001 CAR-T Cells in Patients with Recurrent and Refractory Epithelial Ovarian Cancer, Fallopian Tube Cancer, and Peritoneal Cancer.","Inclusion Criteria:\n\n* Subjects must meet all of the following criteria for admission to this study:\n\nAge≥ 18 years old;\n\n* ECOG performance status score: 0\\~2 points or KPS score≥70 points;\n* Relapsed or refractory epithelial ovarian, fallopian tube and peritoneal cancer confirmed by histology or cytology and have failed, are intolerant or have no standard treatment after standard therapy;\n* Tumor tissue specimens or tumor samples can be obtained by tumor biopsy and other methods;\n* Immunohistochemistry (IHC) staining confirmed that the tumor cells had positive TAG-72 expression (positive definition: \\>). IHC staining intensity of 1% tumor cells ≥2+);\n* Estimated survival time of more than 3 months;\n* At least one evaluable tumor lesion according to RECIST 1.1;\n* Prior to treatment, major organ function met the following criteria (no blood transfusion, long-acting EPO, long-acting G-CSF therapy within 14 days prior to study drug administration, in the case of short-acting EPO, short-acting G-CSF, this criterion can be shortened to 7 days):\n* complete blood count: Absolute neutrophil count (ANC) ≥1.5×109\u002FL,, Absolute lymphocyte count (ALC) ≥ 0.5×109\u002FL; hemoglobin (HGB) ≥ 80 g\u002FL; Platelets (PLT) ≥ 75×109\u002FL;\n* Renal: serum creatinine ≤1.5× upper limit of normal range (ULN);\n* Liver: total bilirubin ≤ 1.5× ULN (including patients with liver metastases or liver cancer), AST and ALT ≤ 2.5× ULN (liver metastases ≤5×ULN);\n* Coagulation: International normalized ratio (INR) or prothrombin time (PT) ≤ 1.5× ULN, partially activated thromboplastin time (APTT) ≤ 1.5× ULN;\n* Must be using adequate contraception during the study and for 6 months after the end of the study, have a negative serum pregnancy test within 7 days prior to proposed enrollment in the study, and must be a non-lactating subject.\n\nExclusion Criteria:\n\n* Subjects who meet any of the following criteria will not be admitted to this study:\n* Those who are allergic to any component of SCT-001 CAR-T cell injection;\n* Received anti-tumor therapy such as chemotherapy, radiotherapy, biological therapy, endocrine therapy, targeted therapy, immunotherapy, etc., or participated in other clinical trials and received 5 half-lives of therapeutic drugs within 4 weeks prior to the first use of the study drug (4 weeks or 5 half-lives, whichever is shorter);\n* Received treatment with traditional Chinese medicine or modern Chinese medicine preparations with anti-tumor indications in the label within 14 days before the first dose;\n* The adverse reactions of previous anti-tumor therapy have not recovered to NCI CTCAE v5.0 grade evaluation ≤ grade 1 (except for toxicity that the investigator judges has no safety risk such as alopecia);\n* Surgical procedure within 4 weeks prior to treatment or has not fully recovered from any previous invasive procedure;\n* Central nervous system metastases or meningeal metastases with clinical symptoms, or other evidence that the subject's central nervous system metastases or meningeal metastases have not been controlled, and are judged by the investigator to be unsuitable for enrollment;\n* Those with active infection (NCI CTCAE v5.0≥ grade 2) or any other person with suspected risk of infection as assessed by the investigator;\n* Has a history of autoimmune disease, immunodeficiency, including a positive HIV test, or has other acquired, congenital immunodeficiency diseases, or has a history of organ transplantation;\n* Subjects with active hepatitis B or active hepatitis C;\n* Those who have used immune cell therapy in the past;\n* History of severe cardiovascular disease, such as severe cardiac rhythm or conduction abnormalities (ventricular arrhythmia requiring clinical intervention, II.\\~III. degree atrioventricular block, etc.), myocardial infarction, history of coronary artery bypass surgery, heart failure, New York College of Cardiology (NYHA) grade II or above, left ventricular ejection fraction (LVEF) ≤50% and thrombosis found, male QTcF \\>450msec or female QTcF \\>470msec, etc.;\n* Subjects with a history of severe cerebrovascular diseases such as stroke;\n* Need to combine with other anti-tumor therapies (including various radiotherapy, chemotherapy, immunotherapy, targeted therapy, traditional Chinese medicine therapy, etc.);\n* Previous clear history of neurological or psychiatric disorders, including epilepsy or dementia;\n* In the opinion of the investigator, the subject has other reasons that make it unsuitable to participate in this clinical study.",{"count":134,"type":20},24,[98],"This study is an open-label, dose-escalation, investigator-initiated phase I interventional clinical study. To evaluate the safety, tolerability and preliminary efficacy of SCT-001 CAR-T cell injection in subjects with relapsed and refractory epithelial ovarian, fallopian tube and peritoneal cancer, and to explore the pharmacokinetic characteristics, biomarker changes and immunogenicity of SCT-001 CAR-T cell injection in subjects with relapsed and refractory epithelial ovarian, fallopian tube and peritoneal cancer.\n\nIn this study, two trial cohorts were set up, cohort 1 was the intraperitoneal route of administration, and the subjects enrolled in cohort 1 needed to meet the conditions for intraperitoneal administration ((1) the subject had a large amount of ascites, (2) the subject was suitable for peritoneal catheterization, (3) the subject had no severe abdominal adhesions, and (4) the subject agreed to undergo intraperitoneal surgical catheterization for intraperitoneal administration); Cohort 2 is the intravenous route.",[26,27,29],"NOT_YET_RECRUITING","2025-02-20",{"date":141,"type":54},"2025-02-26",{"date":143,"type":20},"2025-06-01",{"date":145,"type":20},"2030-06-01",{"name":147,"class":148},"Shanghai Gynecologic Oncology Group","OTHER_GOV",{"id":150,"slug":151,"hasResults":11,"nctId":152,"briefTitle":153,"officialTitle":154,"acronym":155,"eligibilityCriteria":156,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":157,"targetDuration":4,"studyType":72,"phases":4,"briefSummary":159,"conditions":160,"keywords":162,"overallStatus":138,"whyStopped":4,"lastUpdateSubmitDate":167,"lastUpdatePostDateStruct":168,"startDateStruct":170,"completionDateStruct":172,"leadSponsor":174,"locationsCount":176},"100549566","study-and-modulation-of-immune-responses-in-primary-and-metastatic-colon-cancers-100549566","NCT06435689","Study and Modulation of Immune Responses in Primary and Metastatic Colon Cancers","Etude et Modulation de la réponse Immunitaire Dans Les Cancers COlorectaux Primaires et METastatiques","I-COMET","Inclusion Criteria:\n\n* Male or female 18 years of age or older\n* Diagnosis of colorectal adenocarcinoma\n* Scheduled resection of tumor and\u002For metastasis(es)\n\nExclusion Criteria:\n\n* Patient's opposition to research\n* Patients under guardianship\n* The following situations\n\n  1. Persons unable to understand and\u002For read the information leaflet\n  2. Patient with one of the following functions: Investigator or co-investigator, research assistant, pharmacist, study coordinator or, having any involvement in the study\n  3. Non-cooperative or potentially non-compliant person for the study and its procedures with foreseeable difficulties in regular follow-up over 5 years.\n  4. Non-affiliation with a social security scheme, Couverture Médicale Universelle or any equivalent scheme.\n* Pregnant or breast-feeding women.\n* HIV-positive patients.",{"count":158,"type":20},500,"Colorectal cancer (CRC) is the 3rd most common cancer in France. Treatment of CRC relies primarily on surgical removal of the primary tumor and chemotherapy is the current standard of care for synchronous metastatic disease. Overall survival remains strongly correlated with the tumor stage at the time of surgery, from 90% at five years for localized disease (stages 1 and 2), to around 20% for metastatic forms of the disease (stage 4). Recent research in cancer highlights the role of the immune system in the development, evolution and fate of tumors. Understanding the nature of interactions between different immune cells infiltrating the tumor is important for the development of innovative therapies. Recently, the consensus molecular classification of CRC confirmed the importance of the immune response in CRC by showing that a \"high immune response\" is a good prognostic indicator for patients with this pathology. However, immunotherapies are effective for only a minority of patients with metastatic CRC. Indeed, anti Programmed cell Death 1 (anti-PD-1), -PD-L1 immune checkpoint blocking antibodies have only shown effectiveness in patients with microsatellite instability (MSI), which only represents 5% of metastatic CRCs.\n\nThus, the aim of this study is to better understand the role of the immune system on the development of CRC and its possible modulation to treat or prevent metastatic recurrences.",[161,29],"Colon Cancer",[163,164,165,166],"Organoids","T-cells","Metastasis","Immunotherapies","2024-05-26",{"date":169,"type":54},"2024-05-30",{"date":171,"type":20},"2024-06-15",{"date":173,"type":20},"2039-06-15",{"name":175,"class":60},"Assistance Publique - Hôpitaux de Paris",2,{"id":178,"slug":179,"hasResults":11,"nctId":180,"briefTitle":181,"officialTitle":181,"acronym":182,"eligibilityCriteria":183,"healthyVolunteers":11,"sex":68,"minAge":17,"maxAge":184,"enrollmentInfo":185,"targetDuration":186,"studyType":72,"phases":4,"briefSummary":187,"conditions":188,"keywords":4,"overallStatus":138,"whyStopped":4,"lastUpdateSubmitDate":191,"lastUpdatePostDateStruct":192,"startDateStruct":194,"completionDateStruct":196,"leadSponsor":198,"locationsCount":4},"100546331","international-registration-of-isolated-stic-to-report-and-investigate-the-risk-of-serous-peritoneal-carcinomatosis-100546331","NCT06393543","International Registration of Isolated STIC: to Report and Investigate the Risk of Serous Peritoneal Carcinomatosis","STICRISC","Inclusion Criteria:\n\n* Women\n* Bilateral salpingectomy (with or without oophorectomy)\n* A serous tubal intraepithelial carcinoma at histopathological review\n\nExclusion Criteria:\n\n* Invasive cancer at initial surgery or pathological examination (either macroscopic and\u002For microscopic)","100 Years",{"count":71,"type":20},"10 Years","To prospectively assess the incidence of peritoneal carcinomatosis for women with isolated STIC (serous tubal intraepithelial carcinoma). Moreover, to identify histopathological characteristics of STIC which are reproducible and associated to the risk of peritoneal carcinomatosis and to report the findings of additional diagnostics.",[189,190,28,29],"BRCA Mutation","Serous Tubal Intraepithelial Carcinoma","2024-04-26",{"date":193,"type":54},"2024-05-01",{"date":195,"type":20},"2024-06",{"date":197,"type":20},"2034-06",{"name":199,"class":60},"Radboud University Medical Center"]